These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 18342836)

  • 1. Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling.
    Yi X; Wei W; Wang SY; Du ZY; Xu YJ; Yu XD
    Biochem Pharmacol; 2008 May; 75(9):1697-705. PubMed ID: 18342836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.
    Fiskus W; Ren Y; Mohapatra A; Bali P; Mandawat A; Rao R; Herger B; Yang Y; Atadja P; Wu J; Bhalla K
    Clin Cancer Res; 2007 Aug; 13(16):4882-90. PubMed ID: 17699868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitor trichostatin A represses estrogen receptor alpha-dependent transcription and promotes proteasomal degradation of cyclin D1 in human breast carcinoma cell lines.
    Alao JP; Lam EW; Ali S; Buluwela L; Bordogna W; Lockey P; Varshochi R; Stavropoulou AV; Coombes RC; Vigushin DM
    Clin Cancer Res; 2004 Dec; 10(23):8094-104. PubMed ID: 15585645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of proliferation, sprouting, tube formation and Tie2 signaling of lymphatic endothelial cells by the histone deacetylase inhibitor SAHA.
    Cheng HT; Hung WC
    Oncol Rep; 2013 Aug; 30(2):961-7. PubMed ID: 23754070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha.
    Fan M; Park A; Nephew KP
    Mol Endocrinol; 2005 Dec; 19(12):2901-14. PubMed ID: 16037132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells.
    Cheng HT; Hung WC
    Oncol Rep; 2013 Mar; 29(3):1238-44. PubMed ID: 23242251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
    Munster PN; Troso-Sandoval T; Rosen N; Rifkind R; Marks PA; Richon VM
    Cancer Res; 2001 Dec; 61(23):8492-7. PubMed ID: 11731433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.
    Feng X; Han H; Zou D; Zhou J; Zhou W
    Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells.
    De los Santos M; Martínez-Iglesias O; Aranda A
    Endocr Relat Cancer; 2007 Dec; 14(4):1021-8. PubMed ID: 18045953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Inhibitory effect of carbamazepine on proliferation of estrogen-dependent breast cancer cells].
    Meng QW; Zhao CH; Xi YH; Cai L; Sun LC; Sui GJ
    Ai Zheng; 2006 Aug; 25(8):967-73. PubMed ID: 16965676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL.
    Yerbes R; López-Rivas A
    Invest New Drugs; 2012 Apr; 30(2):541-7. PubMed ID: 21107885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
    Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
    Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2.
    Bali P; Pranpat M; Swaby R; Fiskus W; Yamaguchi H; Balasis M; Rocha K; Wang HG; Richon V; Bhalla K
    Clin Cancer Res; 2005 Sep; 11(17):6382-9. PubMed ID: 16144943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
    Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ
    PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis.
    Li D; Marchenko ND; Moll UM
    Cell Death Differ; 2011 Dec; 18(12):1904-13. PubMed ID: 21637290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.
    Butler LM; Liapis V; Bouralexis S; Welldon K; Hay S; Thai le M; Labrinidis A; Tilley WD; Findlay DM; Evdokiou A
    Int J Cancer; 2006 Aug; 119(4):944-54. PubMed ID: 16550602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERα to inhibit the growth of breast cancer induced by oestrogen.
    Zhang N; Sun P; Xu Y; Li H; Liu H; Wang L; Cao Y; Zhou K; TinghuaiWang
    Cancer Lett; 2021 Feb; 498():54-69. PubMed ID: 33069770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells.
    Alao JP; Stavropoulou AV; Lam EW; Coombes RC; Vigushin DM
    Mol Cancer; 2006 Feb; 5():8. PubMed ID: 16504004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
    Luo G; Lin X; Ren S; Wu S; Wang X; Ma L; Xiang H
    Eur J Med Chem; 2021 Dec; 226():113870. PubMed ID: 34610548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.